Credit Suisse Group Analysts Give GlaxoSmithKline (LON:GSK) a GBX 1,700 Price Target
Credit Suisse Group set a GBX 1,700 ($22.21) price objective on GlaxoSmithKline (LON:GSK) in a report issued on Thursday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
A number of other equities analysts also recently issued reports on the stock. Bryan, Garnier & Co cut their price target on shares of GlaxoSmithKline from GBX 1,710 ($22.34) to GBX 1,660 ($21.69) and set a neutral rating for the company in a report on Thursday, May 2nd. Barclays reiterated an underweight rating and issued a $150.00 price target on shares of Tesla in a report on Thursday. UBS Group reiterated a hold rating and issued a $20.50 price target on shares of ABB in a report on Thursday. Goldman Sachs Group downgraded shares of Cadence Bancorp from a buy rating to a neutral rating and set a $18.00 price target for the company. in a report on Monday, July 22nd. Finally, Deutsche Bank reiterated a buy rating and issued a $80.00 price target on shares of Bayerische Motoren Werke in a report on Monday, July 8th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the stock. GlaxoSmithKline presently has a consensus rating of Hold and a consensus price target of GBX 1,632.18 ($21.33).
Shares of GSK opened at GBX 1,705.60 ($22.29) on Thursday. The company has a 50-day moving average of GBX 1,613.63. The company has a debt-to-equity ratio of 942.07, a current ratio of 0.72 and a quick ratio of 0.45. The stock has a market cap of $84.09 billion and a P/E ratio of 21.73. GlaxoSmithKline has a 52-week low of GBX 1,408.80 ($18.41) and a 52-week high of GBX 1,672 ($21.85).
In other GlaxoSmithKline news, insider Manvinder Singh Banga bought 458 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was purchased at an average cost of GBX 1,568 ($20.49) per share, for a total transaction of £7,181.44 ($9,383.82). Also, insider Vivienne Cox bought 434 shares of the company’s stock in a transaction on Wednesday, July 24th. The shares were acquired at an average price of GBX 1,654 ($21.61) per share, with a total value of £7,178.36 ($9,379.80). Insiders have acquired a total of 916 shares of company stock valued at $1,473,771 over the last 90 days.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Article: What does a bar chart display?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.